久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業(yè)有限公司Logo

熱門詞: 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥

當(dāng)前位置: 首頁 > 所有品牌 > MannKind
MannKind
MannKind MannKind

美國MannKind Corporation?
胰島素吸入設(shè)備生產(chǎn)商MannKind Corp


MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA?, is an ultra rapid-acting insulin. We have submitted a new drug application to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

The pharmacokinetic profile of AFREZZA sets it apart from all other insulin products. AFREZZA particles dissolve upon contact with the lung surface, releasing insulin that rapidly enters the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, which more closely mimics the natural release of insulin than any other insulin preparation. In our clinical trials, we have observed that patients using the AFREZZA have achieved significant reductions in post-meal glucose excursions and significant improvements in overall glucose control, as measured in AIC levels, without the weight gain typically associated with insulin therapy.

AFREZZA utilizes our proprietary Technosphere? formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. With AFREZZA, we load human insulin onto the Technosphere particles; however, this technology is not limited to insulin delivery. We believe it represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Beyond convenience, we believe the key advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration.

In addition to our Technosphere platform, we are developing therapies for the treatment of different types of cancer. Our cancer immunotherapy program is advancing to Phase 2 studies in patients with advanced melanoma and we are conducting preclinical studies of a drug candidate for the treatment of certain malignancies and inflammatory diseases.
?

關(guān)于我們客戶服務(wù)產(chǎn)品分類法律聲明
主站蜘蛛池模板: 国产高清在线看 | 亚洲一区二区三区在线 | 国产va在线观看 | 在线观看国产精品入口 | 国产a视频精品免费观看 | 国产成人精品日本亚洲语音2 | 国产欧美精品综合一区 | 国产精品一区二区综合 | 国产精品手机视频一区二区 | 国产成人精品一区二区免费 | 国模私拍一区二区 | 思久久 | 欧美日韩国产精品综合 | 九草伊人 | 国产成人久久一区二区三区 | 狼人综合伊人 | 广东东莞一级毛片免费 | 亚洲欧美二区三区久本道 | 国产成人精品综合久久久 | 欧美我不卡 | 亚洲欧美日韩天堂 | 免费国产一区 | 欧美日韩一二区 | 精品一区二区在线欧美日韩 | 日韩欧美在线综合网高清 | 国产日韩欧美亚洲综合 | 日韩欧美极品 | 精品久久久一二三区 | 午夜啪啪网 | 欧美福利在线视频 | 国产在线视欧美亚综合 | 足交在线观看 | 欧美日韩在线亚洲国产人 | 亚洲国产精品一区二区九九 | 国产一区亚洲欧美成人 | 亚洲国产欧美日韩 | 国产精品久久二区三区色裕 | 综合伊人久久在一二三区 | 国产精品一区二区三 | 久久成人a毛片免费观看网站 | 日韩亚洲欧美综合 |